View Older Stories View More Recent Stories

May 18, 2026 03:46PM Regeneron Pharma (REGN) PT Lowered to $860 at Wolfe Research
May 18, 2026 03:35PM Regeneron (REGN) call put ratio 1 call to 1.2 puts as share price down 9.9%
May 18, 2026 01:08PM Leerink Partners Downgrades Regeneron Pharma (REGN) to Market Perform, 'on LAG-3 Failure and Eylea Erosion Risk'
May 18, 2026 10:27AM Regeneron Pharma (REGN) PT Lowered to $785 at Cantor Fitzgerald on Disappointing Trial Results
May 18, 2026 09:39AM Regeneron Pharma (REGN) PT Lowered to $730 at BMO Capital Following LAG-3 Miss
May 18, 2026 09:17AM Regeneron Pharma (REGN) PT Lowered to $855 at Piper Sandler Following Setback
May 18, 2026 08:47AM Regeneron Pharma (REGN) PT Lowered to $861 at Bernstein SocGen Group
May 18, 2026 05:21AM Regeneron Pharma (REGN) PT Lowered to $778 at Truist Securities
May 18, 2026 05:14AM Regeneron Pharma (REGN) PT Lowered to $707 at RBC Capital
May 18, 2026 01:01AM BofA Securities Reiterates Buy Rating on Regeneron Pharma (REGN)
May 5, 2026 07:01AM Dupixent shows improved esophageal function in phase 4 trial for EoE
Apr 30, 2026 02:49PM Regeneron Pharma (REGN) PT Raised to $995 at Guggenheim
Apr 30, 2026 08:43AM Regeneron Pharma (REGN) PT Lowered to $762 at RBC Capital
Apr 30, 2026 07:34AM Regeneron Pharma (REGN) PT Raised to $916 at Bernstein SocGen Group
Apr 29, 2026 04:21PM Regeneron Pharma (REGN) PT Lowered to $769 at Truist Securities
Apr 29, 2026 12:35PM Regeneron Pharma (REGN) PT Lowered to $902 at Raymond James
Apr 29, 2026 06:31AM Regeneron (REGN) Tops Q1 EPS by 50c, Beats on Revenue
Apr 26, 2026 08:00PM U.S. Biotech stocks: Q1 earnings previews
Apr 24, 2026 09:00AM Piper Sandler on Regeneron Pharma (REGN): 'Channel Checks Point to Branded Anti-VEGF Expansion'
Apr 24, 2026 08:34AM Regeneron Pharma (REGN) PT Lowered to $913 at Bernstein SocGen
Apr 23, 2026 03:46PM Regeneron agrees to lower drug prices, offer gene therapy for free
Apr 23, 2026 12:53PM Regeneron wins FDA approval for gene therapy treating rare hearing loss
Apr 22, 2026 02:56PM Raymond James Reiterates Outperform Rating on Regeneron Pharma (REGN)
Apr 20, 2026 07:30AM Goldman Sachs sees nearly 140% upside in this biopharma stock
Apr 13, 2026 06:31AM Regeneron and Telix form $2.1 billion radiopharmaceutical partnership
Apr 13, 2026 05:52AM Bernstein on US Pharma and Biotech: Who might buy whom?
Apr 10, 2026 08:51AM Piper Sandler Reiterates Overweight Rating on Regeneron Pharma (REGN)
Apr 8, 2026 08:00AM Regeneron Pharma (REGN) Reiterated at Overweight by Cantor Fitzgerald Ahead of Q1 Call
Apr 8, 2026 07:59AM Regeneron Pharma (REGN) PT Lowered to $921 at Bernstein SocGen
Apr 8, 2026 05:07AM Raymond James on Regeneron Pharma (REGN): 'New Survey Indicates 1Q26 Uptick for Eylea HD, More to Come'
Apr 2, 2026 04:31PM Regeneron invests up to $200 million in TriNetX health data partnership
Apr 2, 2026 02:03PM Regeneron: expect to be exempt from the pharma tariffs that it hears are being announced today
Apr 2, 2026 12:01PM FDA approves EYLEA HD for extended dosing up to 20 weeks
Mar 31, 2026 09:41AM Regeneron Pharma (REGN) PT Lowered to $801 at Truist 'To Refresh Risk/Reward'
Mar 31, 2026 04:02AM Piper Sandler Assumes Regeneron Pharma (REGN) at Overweight
Mar 24, 2026 04:19AM Dupixent approved in Japan for bullous pemphigoid treatment
Mar 18, 2026 09:21AM RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
Mar 10, 2026 05:06PM Regeneron Pharma (REGN) PT Raised to $890 at Jefferies
Mar 9, 2026 09:59AM TD Cowen Reiterates Buy Rating on Regeneron Pharma (REGN): "if results are replicated in US, could lead to preferential prescribing"
Mar 9, 2026 09:41AM Truist Securities Reiterates Buy Rating on Regeneron Pharma (REGN) following Ph3 study results
Mar 6, 2026 02:51AM Barclays Starts Regeneron Pharma (REGN) at Overweight
Mar 2, 2026 08:46AM Regeneron Pharma (REGN) PT Raised to $765 at RBC Capital
Feb 27, 2026 07:13AM Dupixent gets European panel backing for young children with chronic hives
Feb 24, 2026 02:23PM Regeneron Pharma (REGN) PT Lowered to $152 at Jefferies
Feb 24, 2026 09:30AM FDA approves Dupixent for allergic fungal rhinosinusitis treatment
Feb 10, 2026 07:00AM Regeneron presents phase 3 data for cat and birch allergy antibody treatments
Feb 9, 2026 07:17AM Regeneron Pharma (REGN) PT Raised to $975 at Guggenheim
Feb 2, 2026 09:25AM BMO Capital on Regeneron Pharma (REGN): 'Commercial Momentum Sets Up 2026'
Feb 2, 2026 07:23AM Regeneron Pharma (REGN) PT Raised to $800 at Cantor Fitzgerald on Commercial Estimates
Feb 2, 2026 07:01AM Regeneron Pharma (REGN) PT Raised to $925 at Bernstein SocGen Group
View More Recent Stories View Older Stories